Assessing eligibility for differentiated service delivery, HIV services utilization and virologic outcomes of adult HIV-infected patients in Sierra Leone: a pre-implementation analysis

Sulaiman Lakoh a,b, Darlinda F. Jiba a, Alren O. Vandy b, Eva Poveda c, Olukemi Adekanmbi d,e, Mariama J. S. Murray f, Gibrilla F. Deen a,b, Foday Sahr a,b, Christopher J. Hoffmann f,g, Jeffrey M. Jacobson h,i, Robert A. Salata j and George A. Yendewa a,l,*

a Department of Medicine, College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone; b Ministry of Health and Sanitation, Freetown, Sierra Leone; c Group of Virology and Pathogenesis, Galicia Sur Health Research Institute (BS Galicia Sur)-Complejo Hospitalario Universitario De Vigo, SERGAS-Uvigo, Spain; d Department of Medicine, College of Medicine, University of Ibadan, Ibadan, Nigeria; e Department of Medicine, University College Hospital, Ibadan, Nigeria; f Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA; g Department of Health, Behavior, and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA; h Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA; i Division of Infectious Diseases and HIV Medicine, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA; j Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA

ABSTRACT

Background: There are limited data to help guide implementation of differentiated HIV service delivery (DSD) in resource-limited settings in sub-Saharan Africa. Objectives: This pre-implementation study sought to assess the proportion of patients eligible for DSD and HIV services utilization, as well as risk factor analysis of virologic failure in Sierra Leone. Methods: We conducted a retrospective study of adult HIV-infected patients aged 18 years and older receiving care at the largest HIV treatment center in Sierra Leone 2019–2020. Multiple logistic regression was used to identify predictors of virologic failure. Results: Of 586 unique patients reviewed, 210 (35.8%) qualified as ‘stable’ for antiretroviral therapy (ART) delivery. There was high utilization of certain HIV service programs (e.g. HIV status disclosure to partners (83%) and treatment ‘buddy’ program participation (62.8%)), while other service programs (e.g. partner testing and community HIV support group participation) had low utilization (<50%). Of 429 patients with available viral load, 277 (64.6%) were virologically suppressed. In the multivariate logistic regression analysis of risk factors of virologic failure, CD4 < 350 cells/mm 3 (p = 0.009), atazanavir-based ART (p = 0.032), once monthly versus once two- or three-monthly ART dispensing (p = 0.028), history of ART switching (p = 0.02), poor adherence (p = 0.001) and not having received adherence support (p < 0.001) were independent predictors of virologic failure. Conclusion: Approximately one in three HIV-infected patients on ART were eligible for DSD. We identified gaps in HIV care (i.e. low partner testing, treatment ‘buddy’, program participation and a substantially high rate of virologic failure) that need to be addressed in preparation for full implementation of DSD in Sierra Leone.

BACKGROUND

The global scale-up of antiretroviral therapy (ART) has significantly improved the survival and quality of life of people living with HIV (PLWH) [1]. Despite this, an estimated one-third (12.6 million) of the 38 million PLWH globally did not have access to lifesaving treatment in 2019 [1]. To address the treatment gap and maximize the benefit of ART, current guidelines recommend treating all who test positive for HIV, regardless of immunological or clinical status [2–4]. The anticipated increase in treatment demand from adopting the ‘treat all’ strategy is likely to overwhelm already fragile health systems and exacerbate the longstanding financial and human resource constraints thwarting HIV control efforts in low-and-middle-income countries (LMICs). From a service delivery perspective, treatment programs must transform primarily facility-based and physician-led health systems into decentralized and more individualized care models suited to the needs and preferences of the diverse patient populations they must now serve.

The World Health Organization (WHO) and the International AIDS Society (IAS) have provided recommendations to guide treatment programs in LMICs adapt and diversify HIV services using ‘differentiated’ service frameworks [2,5]. Differentiated service delivery (DSD) is a client-centered approach that
addresses the health needs of patients taking into account their clinical status, context and preferences [2,5]. Depending on patient characteristics, DSD models vary service intensity (e.g. laboratory monitoring); location (e.g. facility- versus community-based); frequency (e.g. multi-month ART refills) and provider (e.g. task-shifting from physicians or nurses to community health workers) to improve quality of care and health system efficiency [2,5]. Thus, a patient classified as stable may require fewer clinic visits and laboratory monitoring, allowing health care resources to be directed to sicker patients requiring more intensive interventions.

Sierra Leone is one of several LMICs in the West and Central Africa region currently undertaking activities to improve HIV care, in response to specific warnings from the WHO and IAS that this region was lagging behind others in meeting the 90–90–90 goals [6,7]. The national HIV seroprevalence rate of Sierra Leone has remained at 1.5% to 1.7%, yet fewer than 30% of PLWH were receiving ART in 2018, with 26% of those on treatment achieving viral suppression [8]. Studies by our group have identified other entrenched challenges in the local HIV care continuum, suggesting a dynamic epidemic that is characterized by a high prevalence of late-stage presentation and AIDS-related mortality, and rising rates of HIV drug resistance [9–12].

In 2018, the National AIDS Control Program of the Ministry of Health and Sanitation of Sierra Leone released its ‘Guide of Differentiated Care Models in Sierra Leone’, which proposed various DSD models of pediatric and adult HIV care, with ART delivery to clinically stable clients identified as a priority area of focus [13]. Implementation of DSD in Sierra Leone was tentatively set for 2021. To ensure a successful transition, various pilot-level activities that can be considered DSD models have been underway. These include scaling-up of viral load (VL) monitoring and strengthening of client-centered services such as HIV status disclosure and partner testing, targeted adherence counseling and treatment ‘buddy’ and community ART program participation to improve treatment adherence. The advent of the COVID-19 pandemic has necessitated the fast-tracking of DSD rollout plans, which has introduced new implementation complexities warranting the modification of DSD models to support social distancing measures such as fewer clinic visits and multi-monthly ART dispensing [14–18]. However, the overall impact of these pre-implementations measures on HIV service utilization and treatment outcomes have not been fully assessed. Additionally, the proportion of PLWH who qualify for enrollment into specific DSD models remains unknown, making program planning and budgeting difficult for public health experts and policymakers.

The aims of this DSD pre-implementation analysis were to (i) estimate the proportion of adult PLWH receiving care at the largest HIV treatment center in Sierra Leone who meet eligibility criteria for the proposed DSD model for ART delivery to stable clients; (ii) assess the utilization of client-centered services in an attempt to identify potential barriers to service delivery; and (iii) perform a risk factor analysis for virologic failure, an important treatment outcome measure and major criterion for DSD eligibility.

METHODS

Study design, site and population

We conducted a retrospective study of adult HIV-infected patients aged ≥18 years who received care at the HIV Clinic at Connaught Hospital in Freetown, Sierra Leone before the onset of the COVID-19 pandemic (October 2019 through February 2020). Connaught Hospital is a 300-bed academic facility that is affiliated with the College of Medicine and Allied Health Sciences of the University of Sierra Leone and is the country’s main referral hospital for adults. The HIV Clinic at Connaught Hospital in Freetown is the largest HIV treatment center in Sierra Leone and provides both outpatient and inpatient HIV services including partner testing and counseling, prevention of mother-to-child transmission and treatment of opportunistic infections.

Clinical data collection and definitions

Demographic and clinical data were extracted from medical records of HIV-infected patients, who were then classified as clinically stable or unstable using the criteria proposed by the National AIDS Control Program of Sierra Leone (Table 1) [13]. A clinically stable patient was defined as fulfilling all of the

| Table 1. Classification of adult HIV-infected patients based on DSD criteria for ART delivery in Sierra Leone*. |
|-------------------|-------------------|
| **Stable Patient** | **Unstable patient** |
| A patient is considered stable if fulfills ALL of the following: | A patient is considered unstable if has ANY of the following: |
| ● On current ART regimen ≥12 months | ● On current ART regimen <12 months |
| ● No active OIs (including TB) in the previous 6 months | ● Any active OIs (including TB) in the previous 6 months |
| ● Adherent for the previous 6 months | ● Poor or questionable adherence in the previous 6 months |
| ● Most recent viral load <1,000 copies/mL | ● Most recent viral load ≥1,000 copies/mL |
| ● Body mass index ≥18.5 kg/m² | ● Body mass index <18.5 kg/m² |
| ● Age ≥20 years | ● Age <20 years |
| ● Healthcare team does not have concerns about providing longer follow-up intervals for the patient | ● Pregnant or breastfeeding |
| ● Healthcare team has concerns about providing longer follow-up intervals for the patient |

*Reproduced from the National AIDS Control Programme, Ministry of Health and Sanitation of Sierra Leone [13].

Antiretroviral therapy, ART; opportunistic infection, OI; tuberculosis, TB.
following criteria: age 20 years or older, on current ART ≥ 1 year, having no active opportunistic infections’ including tuberculosis (TB) in the previous 6 months, adherent to treatment for the previous 6 months, most recent VL < 1000 copies/mL and body mass index (BMI) ≥18.5 kg/m², in addition to health care team not having any concerns about providing longer follow-up intervals for the patient [13]. A patient who failed to meet any one of the aforementioned criteria was classified as an unstable patient (Table 1).

The WHO has defined virologic failure as VL > 1000 copies/mL based on two consecutive measurements taken at least 3 months apart, with documented adherence support, after taking ART for at least 6 months [2]. However, due to the limited laboratory facilities in most resource-limited settings, various definitions of ‘stable’ clients and virologic failure have emerged, with several DSD models in SSA including the proposed models for Sierra Leone defining virologic failure as a single measurement of VL > 1000 copies/mL obtained at least 12 months after ART initiation [5,13].

Antiretroviral drug substitution was defined as replacing one antiretroviral drug with another, while ART switching was defined as replacing the entire regimen of all three drugs. The commonest reasons recorded for ART substitution were suspected/confirmed drug toxicities and for preventing drug-drug interactions (e.g. substituting boosted-protease inhibitors with efavirenz, EFV, in patients receiving treatment for TB). On the other hand, ART switching was commonly carried out in the event of suspected virologic failure – HIV genotyping is currently not available in Sierra Leone to confirm the presence of drug resistance mutations.

Self-reporting of missed doses, pill counts and reviewing pharmacy refill records and clinic attendance registers were used to access treatment adherence. The Adherence Index was then calculated using the formula [(Total number of pills taken)−(Total number of pills prescribed)] x100%. Good adherence was defined as an adherence index > 95%.

Alcohol use was defined as consuming > 20 g or 2 drinks of an alcoholic beverage daily, while illicit drug use was defined as using any quantity of any of marijuana, cocaine or injected heroin in the last 30 days.

**Statistical analyses**

Statistical analyses were performed using the SPSS Version 25.0 (Armonk, NY; IBM Corp.). Categorical variables were reported as frequencies (percentages) and associations assessed using Pearson’s chi-square or Fisher’s exact tests. Continuous variables were presented as medians (interquartile ranges, IQR) and associations assessed using the non-parametric independent samples Mann–Whitney U-test. A logistic regression model was used to identify predictors of virologic failure. Risk factors known to be associated with virologic failure were accessed in the univariate analysis. These included age, gender, educational level, employment status, relationship status, immunologic status (CD4 count), ART regimen based on drug class, history of ART substitution or switching, treatment duration, level of treatment adherence, targeted adherence support and counselling received, comorbidities (history of tuberculosis) and social risk factors (alcohol and illicit drug use). Other than age and gender which were included a priori, only variables that attained a p-value of <0.2 in the univariate analysis were included in the multivariate regression model. Associations were reported as crude (OR) and adjusted odds ratios (aOR) with 95% confidence intervals (CI). Differences were considered statistically significant when p was <0.05.

**RESULTS**

**Proportion of HIV-infected patients eligible as clinically stable for ART delivery**

Medical records of 586 unique patient visits to the HIV Clinic at Connaught Hospital during October 2019 through February 2020 were available for review, which was representative of the 6-monthly clinic attendance rate (Figure 1). Of these, 12.3% (72/586) were diagnosed and initiated on ART for less than 12 months and were therefore excluded from the analysis. The DSD eligibility criteria (Table 1) were then applied to the remaining 87.7% (514/586) who were on ART for at least 12 months, of which 35.8% (210/586) met the eligibility criteria as stable for ART delivery, while 51.9% (304/586) were ineligible. The commonest reasons for DSD ineligibility (not mutually exclusive) were VL > 1000 copies/mL (37.2%, 218/586), being on ART for at least 12 months but not having a VL measurement in the last 12 months (14.5%, 85/586), being on ART for less than 12 months and recent history of TB (11.9%, 70/586).

**Demographic and clinical characteristics of stable and unstable patients**

Table 2 displays the demographic and clinical characteristics and HIV service utilization of the 514 patients who were on ART for at least 12 months. The majority of patients were female (75.3%, 387/514), had attained secondary education or higher (56.4%, 290/514) and worked in the informal sector (75.5%, 388/514). About 40% (206/514) were married (40.1%, 206/514). The commonest ART regimens
were tenofovir (TDF)- (66.1%, 340/514) and EFV- (57.0%, 293/514) based. The median duration on ART was 6.0 years (IQR 3.0–9.0).

CD4 count was available for 62.1% (319/514) of patients screened, with a median of 322 cells/mm³ (IQR 198–509). VL was available for 82.8% (429/514) of patients, of whom 64.6% (277/429) were virologically suppressed (i.e. VL <1000 copies/mL).

Compared with unstable patients, stable patients were older (median age, 41 versus 38 years; p = 0.01), had higher BMIs (median, 24 versus 22 kg/m²; p < 0.001) and had higher CD4 counts (median, 355 versus 310 cells/mm³; p < 0.001).

### Utilization of HIV services

Overall, 46.9% (241/514) of patients received ART refills monthly, while the remainder had multi-monthly refills. Compared with stable patients, the majority of unstable patients received one-monthly refills (68.9% versus 31.1%; p < 0.001), while most patients who qualified as stable received 3-monthly refills (58.3% versus 41.7%; p < 0.001).

HIV status disclosure was high (82.3%, 423/514), with partner testing and HIV positivity rates of 45.1% (232/514) and 46.6% (108/232), respectively. The commonest reason for HIV status non-disclosure was fear of stigmatization (76.9%, 70/91).

Community HIV support group participation was low (17.7%, 91/514), while nearly two-thirds of patients (63.8%, 323/514) had treatment buddies. ART adherence was estimated as high during the preceding 6 months (86.6%, 445/514). Nearly half of all patients received targeted adherence counselling at least once in the preceding 6 months (46.5%, 239/514).

### Risk factor analysis of virologic failure

Table 3 displays the associations between virologic failure and potential risk factors. After adjusting for confounders in the multivariate regression analysis, there was strong evidence of an association between virologic failure and CD4 < 350 cells/mm³ (aOR 2.83, 95% CI [1.29–6.21]; p = 0.009), ritonavir-boosted atazanavir (ATV/r)-based ART compared with EFV-based regimens (aOR 5.46, 95% CI [1.16–25.64]; p = 0.032), one-monthly versus multi-monthly ART dispensing (aOR 2.53, 95% CI [1.11–5.78]; p = 0.028), history of switching ART (aOR 3.97, 95% CI [1.25–12.66]; p = 0.02), history of poor treatment adherence (aOR 10.87, 95% CI [2.75–43.05]; p = 0.001) and not having received targeted adherence counselling during the preceding 6 months (aOR 10.20, 95% CI [4.07–25.64]; p < 0.001).

### Discussion

This pre-implementation analysis sought to address the paucity of knowledge on HIV service delivery in Sierra Leone as the country prepares to rollout DSD models for ART. We estimated that over one-third (35.8%) of recent adult clinic attendees at the largest HIV treatment center in Sierra Leone met the eligibility criteria as stable clients for DSD. Because differentiating HIV care is a relatively new approach to service delivery in SSA, data on eligibility for DSD models are limited and difficult to compare, given

---

**Figure 1.** Estimation of proportion of stable HIV-infected clients qualifying for DSD model for ART delivery at Connaught Hospital in Freetown, Sierra Leone.
Table 2. Demographic and clinical characteristics of clinically stable and unstable patients.

| Characteristics                        | Total (N = 514) | Stable patients (N = 210) | Unstable patients (N = 304) | p-Value |
|----------------------------------------|-----------------|---------------------------|----------------------------|---------|
| **Gender**                             |                 |                           |                            |         |
| Male                                   | 127 (24.7)      | 49 (23.3)                 | 78 (25.7)                  | 0.548   |
| Female                                 | 387 (75.3)      | 161 (76.7)                | 226 (74.3)                 |         |
| **Age, years**                         |                 |                           |                            |         |
| Median, IQR                            | 39 (32–48)      | 41 (34–50)                | 38 (31–47)                 | 0.010   |
| < 30                                   | 86 (16.7)       | 24 (11.4)                 | 62 (20.4)                  |         |
| 30–39                                  | 165 (32.1)      | 66 (31.4)                 | 109 (35.9)                 |         |
| ≥ 50                                   | 181 (35.2)      | 64 (30.5)                 | 74 (24.3)                  |         |
| **Body mass index, kg/m²** (N = 487)   |                 |                           |                            |         |
| Median, IQR                            | 23 (20–26)      | 24 (21–27)                | 22 (20–25)                 | <0.001  |
| <18.5 (underweight)                    | 43 (8.8)        | -                         | 43 (15.1)                  |         |
| 18.5–24.9 (normal)                     | 271 (53.6)      | 120 (59.4)                | 151 (53.0)                 |         |
| 25–29.9 (overweight)                   | 123 (25.3)      | 60 (29.7)                 | 63 (21.1)                  |         |
| ≥30 (obese)                            | 50 (10.3)       | 22 (10.9)                 | 28 (9.8)                   |         |
| **Educational level attained**          |                 |                           |                            |         |
| None                                   | 135 (26.3)      | 60 (28.6)                 | 75 (24.7)                  | 0.804   |
| Primary                                | 89 (17.3)       | 35 (16.7)                 | 54 (17.8)                  |         |
| Secondary                              | 216 (42.0)      | 86 (41.0)                 | 130 (42.8)                 |         |
| Tertiary                               | 74 (14.4)       | 29 (13.8)                 | 45 (14.8)                  |         |
| **Occupation**                         |                 |                           |                            |         |
| Formal sector                          | 42 (8.2)        | 20 (9.5)                  | 22 (7.2)                   | 0.324   |
| Informal sector                        | 386 (75.5)      | 161 (76.7)                | 227 (74.7)                 |         |
| Unemployed                             | 84 (16.3)       | 29 (13.8)                 | 55 (18.1)                  |         |
| **Relationship status**                |                 |                           |                            |         |
| Single                                 | 154 (30.0)      | 52 (24.8)                 | 102 (33.6)                 | 0.171   |
| Married                                | 206 (40.1)      | 88 (41.9)                 | 118 (38.8)                 |         |
| Divorced                               | 33 (6.4)        | 14 (6.7)                  | 19 (6.3)                   |         |
| Widowed                                | 121 (23.5)      | 56 (26.7)                 | 65 (21.4)                  |         |
| **Smoking**                            |                 |                           |                            |         |
| Yes                                    | 25 (4.9)        | 5 (2.4)                   | 20 (6.6)                   | 0.030   |
| No                                     | 489 (95.1)      | 205 (97.6)                | 284 (93.4)                 |         |
| **Alcohol drinking**                   |                 |                           |                            |         |
| Yes                                    | 52 (10.1)       | 22 (10.5)                 | 30 (9.9)                   | 0.822   |
| No                                     | 462 (89.9)      | 188 (89.5)                | 274 (90.1)                 |         |
| **Illicit drug use**                   |                 |                           |                            |         |
| Yes                                    | 14 (2.7)        | 3 (1.4)                   | 11 (3.6)                   | 0.134   |
| No                                     | 500 (97.3)      | 207 (98.6)                | 293 (96.3)                 |         |
| **History of tuberculosis**            |                 |                           |                            |         |
| Yes                                    | 70 (13.6)       | -                         | 70 (23.0)                  | <0.001  |
| No                                     | 444 (86.4)      | 210 (100)                 | 234 (77.0)                 |         |
| **Last CD4, cells/mm³** (N = 319)      |                 |                           |                            |         |
| Median, IQR                            | 322 (198–509)   | 355 (217–544)             | 310 (179–492)              | 0.089   |
| 0–349                                  | 175 (54.9)      | 68 (49.3)                 | 107 (59.1)                 |         |
| ≥350                                   | 144 (45.1)      | 70 (50.7)                 | 74 (40.9)                  |         |
| **ART regimen by NRTI**                |                 |                           |                            |         |
| ABC-based                              | 10 (1.9)        | 2 (1.0)                   | 8 (2.6)                    | 0.167   |
| AZT-based                              | 164 (31.9)      | 75 (35.7)                 | 89 (29.3)                  |         |
| TDF-based                              | 340 (66.1)      | 133 (63.3)                | 207 (68.1)                 |         |
| **ART regimen by PI or NNRTI**         |                 |                           |                            |         |
| ATV/r-based                            | 80 (15.6)       | 9 (4.3)                   | 71 (23.4)                  | <0.001  |
| LPV/r-based                            | 30 (5.8)        | 10 (4.8)                  | 20 (6.6)                   |         |
| NVP-based                              | 111 (21.6)      | 58 (27.6)                 | 53 (17.4)                  |         |
| EFV-based                              | 293 (57.0)      | 133 (63.3)                | 160 (52.6)                 |         |
| **ART duration, years**                |                 |                           |                            |         |
| Median, IQR                            | 6.0 (3.0–9.0)   | 6.0 (3.0–10.0)            | 6.0 (3.0–6.0)              | 0.038   |
| < 2                                    | 105 (20.4)      | 32 (15.2)                 | 73 (24.0)                  |         |
| 2–5                                    | 165 (32.1)      | 74 (35.2)                 | 91 (29.9)                  |         |
| 6–10                                   | 181 (35.2)      | 72 (34.3)                 | 109 (35.9)                 |         |
| > 10                                   | 63 (12.3)       | 32 (15.2)                 | 31 (10.2)                  |         |
| **ART refill frequency**               |                 |                           |                            |         |
| 1-monthly                              | 241 (46.9)      | 75 (35.7)                 | 166 (54.6)                 | <0.001  |
| 2-monthly                              | 146 (28.4)      | 61 (29.0)                 | 85 (28.0)                  |         |
| 3-monthly                              | 127 (24.7)      | 74 (35.2)                 | 53 (17.4)                  |         |
| **Good ART adherence**                 |                 |                           |                            |         |
| Yes                                    | 445 (86.6)      | 210 (100)                 | 235 (77.3)                 | <0.001  |
| No                                     | 69 (13.4)       | -                         | 69 (22.7)                  |         |
| **Received targeted adherence counselling in last 6 months** |                 |                           |                            | <0.001  |
| None                                   | 275 (53.5)      | 141 (67.1)                | 134 (44.1)                 |         |
| Once                                   | 147 (28.6)      | 65 (31.0)                 | 82 (27.0)                  |         |
| Twice                                  | 66 (12.8)       | 4 (1.9)                   | 62 (20.4)                  |         |
| Three or more times                    | 26 (5.1)        | -                         | 26 (8.6)                   |         |
| **Community HIV support group participation** |             |                           |                            | 0.507   |
| Yes                                    | 91 (17.7)       | 40 (19.0)                 | 51 (16.8)                  |         |

(Continued)
that stability criteria can vary widely across different contexts and settings [2,5]. To further illustrate this point, a recent sub-study from a large randomized trial from two high-prevalence countries (Malawi and Zambia) approximated that 75% (n = 2938) of adult patients screened at 30 ART clinics qualified as stable for ART delivery; however, the eligibility criteria did not include viral suppression, as VL monitoring was not widely available at many of the study sites [19]. Despite these limitations, eligibility estimates could serve as a useful metric for assessing treatment program performance and can help guide program planning, budgeting and funding allocation.

Scaling-up HIV services and optimizing clients’ access are critical to ensuring implementation success; thus, barriers that hinder these processes should be identified and addressed accordingly. Several studies from SSA have emphasized the centrality of reliable and affordable laboratory services for successful navigation of the HIV care continuum [20–22]. In our analysis, we observed gaps in laboratory monitoring, with approximately 62% of patients screened having a CD4 count within the last 12 months while 83% had viral load monitoring within the same time period. Of note, viral load monitoring was first piloted in Sierra Leone in 2011 and has been operating at scale since 2017. Of the other HIV services that were scaled-up in anticipation of DSD rollout, there was a high utilization of HIV status disclosure (83%) and participation in the treatment ‘buddy’ program (62.8%), while partner testing, community HIV community support group participation and targeted adherence counselling had lower rates of utilization (<50%). Fear of stigmatization remains entrenched in this setting as was previously reported by Kelly et al. and others [23–25] and was the most common reason (77%) for non-disclosure of HIV status. Thus, our findings suggest that while improvements have been made in many aspects of HIV service utilization, more resources are needed in other areas to bring the program up to readiness for full DSD implementation.

The goals of ART are to achieve and maintain durable viral suppression and restore immune function. From a prevention standpoint, sustained viral suppression is one of the most potent public health tools for interrupting the HIV transmission cycle (undetectable equals untransmittable) and limiting the emergence of drug resistance mutations [2–4,26]. To the best of our knowledge, this is the first study to assess virologic outcomes of HIV-infected patients receiving ART in Sierra Leone. Of the 429 patients who had VL measurements in the preceding 12 months, about two-thirds (64%) were virally suppressed, which was over twice the national rate of <30% achieved in 2018 [1].

Virologic failure remains a major barrier hindering the success of ART programs in SSA [1,6]. In our study, virologic failure was predicted by similar biological and behavioral factors that have been

| Characteristics | Total (N = 514) | Stable patients (N = 210) | Unstable patients (N = 304) | p-Value |
|-----------------|----------------|--------------------------|-----------------------------|---------|
| No              | 423 (82.3)     | 170 (81.0)               | 253 (83.2)                  |         |
| Has treatment ‘buddy’ |              |                          |                             |         |
| Yes             | 323 (62.8)     | 130 (61.9)               | 193 (63.5)                  | 0.715   |
| No              | 191 (37.2)     | 80 (38.1)                | 111 (36.5)                  |         |
| Disclosed HIV status |              |                          |                             |         |
| Yes             | 423 (82.3)     | 176 (83.8)               | 247 (81.3)                  | 0.455   |
| No              | 91 (17.7)      | 34 (16.2)                | 57 (18.8)                   |         |
| Reasons for nondisclosure of HIV status (N = 91) | | | |
| Fear of stigmatization | 70 (76.9) | 28 (80.0) | 42 (75.0) | 0.784 |
| Fear of discrimination | 6 (6.6)  | 2 (5.7)     | 4 (7.1)    |         |
| Fear of abandonment  | 6 (6.6)  | 1 (2.9)     | 5 (8.9)    |         |
| No reason | 9 (9.9) | 4 (11.4) | 5 (8.9) |         |
| Partner tested for HIV | | | |
| Yes | 232 (45.1) | 109 (51.9) | 123 (40.5) | 0.010 |
| No | 282 (54.9) | 101 (48.1) | 181 (59.5) |         |
| Partner HIV status (N = 232) | | | |
| Positive | 108 (46.6) | 53 (48.6) | 55 (44.7) | 0.551 |
| Negative | 124 (53.4) | 56 (51.4) | 68 (55.3) |         |

Antiretroviral therapy, ART; protease inhibitor, PI; nucleoside reverse transcription inhibitor, NRTI; non-nucleoside reverse transcription inhibitor, NNRTI.
| Risk factors                      | Viologic outcome | Univariate analysis | Multivariate analysis |
|----------------------------------|------------------|---------------------|----------------------|
|                                  | Failure (N = 152) | Suppressed (N = 277) |                      |                      |
| Gender                           |                  |                     |                      |                      |
| Male                             | 35 (23.0)        | 59 (21.3)           | Ref                  | 0.679                | Ref                  | 0.512                |
| Female                           | 117 (77.0)       | 218 (78.7)          | 0.90 (0.56–1.45)     | 0.73 (0.28–1.88)     |                      |                      |
| Age, years                       |                  |                     |                      |                      |
| < 30                             | 24 (15.8)        | 40 (14.4)           | 1.11 (0.64–1.93)     | 0.708                | Ref                  | 0.622                |
| ≥ 30                             | 128 (84.2)       | 237 (85.6)          | Ref                  |                      |                      |                      |
| Body mass index, kg/m² (N = 407) |                  |                     |                      |                      |                      |                      |
| <18.5                            | 13 (9.2)         | 29 (10.9)           | 0.83 (0.42–1.65)     | 0.595                |                      |                      |
| ≥ 18.5                           | 128 (90.8)       | 237 (89.1)          | Ref                  |                      |                      |                      |
| Education                        |                  |                     |                      |                      |                      |                      |
| None or primary                  | 69 (45.4)        | 122 (44.0)          | 1.06 (0.71–1.57)     | 0.710                |                      |                      |
| Secondary or tertiary            | 83 (54.6)        | 155 (56.0)          | Ref                  |                      |                      |                      |
| Occupation                       |                  |                     |                      |                      |                      |                      |
| Employed                         | 124 (49.4)       | 231 (65.1)          | Ref                  | 0.634                |                      |                      |
| Unemployed                       | 28 (37.8)        | 46 (62.2)           | 1.13 (0.68–1.90)     |                      |                      |                      |
| Smoking                          |                  |                     |                      |                      |                      |                      |
| Yes                              | 8 (5.3)          | 8 (2.9)             | 1.87 (0.69–5.08)     | 0.286                |                      |                      |
| No                               | 144 (94.7)       | 269 (97.1)          | Ref                  |                      |                      |                      |
| Alcohol/illicit drug use         |                  |                     |                      |                      |                      |                      |
| Yes                              | 14 (9.2)         | 27 (9.7)            | 0.94 (0.48–1.85)     | 0.856                |                      |                      |
| No                               | 138 (90.8)       | 250 (90.3)          | Ref                  |                      |                      |                      |
| History of tuberculosis          |                  |                     |                      |                      |                      |                      |
| Yes                              | 22 (14.5)        | 40 (14.4)           | 1.00 (0.57–1.76)     | 1.000                |                      |                      |
| No                               | 130 (85.5)       | 237 (85.6)          | Ref                  |                      |                      |                      |
| Last CD4, cells/mm³ (N = 261)    |                  |                     |                      |                      |                      |                      |
| <350                             | 54 (68.4)        | 90 (49.5)           | 2.21 (1.27–3.85)     | 0.005                | 2.83 (1.29–6.21)     | 0.009                |
| ≥350                             | 25 (31.6)        | 92 (50.5)           | Ref                  |                      | Ref                  |                      |
| ART regimen by NRTI              |                  |                     |                      |                      |                      |                      |
| ABC-based                        | 7 (4.6)          | 2 (0.7)             | 6.76 (1.38–33.33)    | 0.019                | 1.12 (0.05–23.81)    | 0.942                |
| AZT-based                        | 54 (35.5)        | 99 (35.7)           | 1.05 (0.69–1.60)     | 0.802                | 1.46 (0.42–5.13)     | 0.552                |
| TDF-based                        | 91 (59.9)        | 176 (63.5)          | Ref                  |                      | Ref                  |                      |
| ART regimen by PI or NRTI        |                  |                     |                      |                      |                      |                      |
| ATV/r-based                      | 58 (38.2)        | 10 (3.6)            | 23.10 (11.0–47.62)   | <0.001               | 5.46 (1.16–25.64)    | 0.032                |
| LPV/r-based                      | 15 (9.9)         | 11 (4.0)            | 5.43 (2.34–12.66)    | <0.001               | 3.70 (0.49–27.78)    | 0.206                |
| NVP-based                        | 32 (21.1)        | 69 (24.9)           | 1.85 (1.09–3.13)     | 0.023                | 1.46 (0.37–5.78)     | 0.386                |
| EFV-based                        | 47 (30.9)        | 187 (67.5)          | Ref                  |                      | Ref                  |                      |
| ART refill frequency             |                  |                     |                      |                      |                      |                      |
| 1-monthly                        | 102 (67.1)       | 92 (33.2)           | 4.10 (2.69–6.25)     | <0.001               | 2.53 (1.11–5.78)     | 0.028                |
| 2- or 3-monthly                  | 50 (32.9)        | 185 (66.8)          | Ref                  |                      | Ref                  |                      |
| History of ART change            |                  |                     |                      |                      |                      |                      |
| Substitution (1 drug)            | 16 (10.5)        | 17 (6.1)            | 3.26 (1.56–6.80)     | 0.002                | 1.55 (0.29–8.23)     | 0.610                |
| Switch (2 or more drugs)         | 69 (45.4)        | 28 (10.1)           | 8.56 (5.10–14.29)    | <0.001               | 3.97 (1.25–12.66)    | 0.020                |
| No change                        | 67 (44.1)        | 232 (83.8)          | Ref                  |                      | Ref                  |                      |
| ART treatment duration           |                  |                     |                      |                      |                      |                      |
| < 2                              | 21 (26)          | 46 (68.7)           | 0.96 (0.45–2.04)     | 0.918                |                      |                      |
| 2–5                              | 46 (6)           | 96 (67.6)           | 1.01 (0.53–1.93)     | 0.979                |                      |                      |
| 6–10                             | 66 (41.0)        | 95 (59.0)           | 1.46 (0.78–2.75)     | 0.237                |                      |                      |
| > 10                             | 19 (32.2)        | 40 (67.8)           |                      |                      |                      |                      |
| Good ART adherence               |                  |                     |                      |                      |                      |                      |
| Yes                              | 111 (73.0)       | 269 (97.1)          | <0.001               |                      |                      | <0.001               |
| No                               | 41 (27.0)        | 8 (2.9)             | 12.35 (5.65–27.03)   | 10.87 (2.75–43.05)   |                      |                      |
| Received targeted adherence counselling in previous 6 months | | | | | | | | |
| Yes                              | 136 (89.5)       | 103 (37.2)          | Ref                  |                      |                      | <0.001               |
| No                               | 16 (10.5)        | 174 (62.8)          | 14.36 (6.10–25.45)   | <0.001               | 10.20 (4.07–25.64)   |                      |
| Community HIV support group participation | | | | | | | | | |
| Yes                              | 33               | 53 (61.6)           | 1.17 (0.72–1.91)     | 0.524                |                      |                      |
| No                               | 119 (34.7)       | 224 (65.3)          | Ref                  |                      |                      |                      |
| Has treatment ‘buddy’            |                  |                     |                      |                      |                      |                      |
| Yes                              | 97 (63.8)        | 179 (64.6)          | 0.97 (0.64–1.46)     | 0.868                |                      |                      |
| No                               | 55 (36.2)        | 98 (35.4)           | Ref                  |                      |                      |                      |

Antiretroviral therapy, ART; confidence interval, CI; nucleos(t)ide reverse transcription inhibitor, NRTI; non-nucleos(t)ide reverse transcription inhibitor, NNRTI; protease inhibitor, PI.
Antiretroviral therapy substitution was most commonly carried out in the event of suspected HIV drug resistance (HIVDR). According to recent WHO reports, the prevalence of HIVDR is increasing globally, with countries in SSA being the worst affected [31]. The WHO has called for the integration of HIVDR monitoring and management strategies into broader HIV prevention and control efforts; however, Sierra Leone and similar resource-limited settings lack the laboratory capacity to do so [32]. Thus, we were unable to assess the prevalence and impact of HIVDR on treatment outcomes in this cohort. Nonetheless, we hypothesize that high rates of HIVDR could partly explain the high rates of virologic failure in this setting. Of note, in the only study to date from Sierra Leone characterizing HIVDR, we previously observed a high prevalence of acquired HIVDR (>95%) in an unrelated cohort of HIV-infected individuals (n = 151) aged >18 years at this same facility [12].

Over half (52%) of clinic attendees had been on ART for more than 12 months and were otherwise well but were classified as ‘unstable clients’. The commonest reasons were elevated VL (>1000 copies/mm$^3$) (37.2%) and lack of VL measurement in the preceding 12 months (14.5%). This is a substantial proportion of patients of in HIV care and are the focus of current efforts aimed at improving clinical outcomes. Our analysis of services utilization and risk factors of poor virologic outcomes offers insights into strategies that could help this large pool of clients achieve better treatment outcomes and increase the number of stable patients. These include measures to increase clinic attendance, processes to streamline VL testing for clients, increasing adherence support for patients failing on ART and multi-monthly ART dispensing. More research is needed to identify factors and processes that could improve HIV services up and virologic outcomes in this setting.

Our study had strengths and weaknesses worthy of note. This was a quantitative analysis from a single (though largest) HIV treatment center in Sierra Leone, which may limit its generalizability. Secondly, analysis of potential barriers to accessing and utilization of HIV services and virologic outcomes were not exhaustive, due to the retrospective nature of the study design and limited data available for analysis. Another limitation was that we were unable to assess the implementation, service and client outcome measures of feasibility, acceptability, adoption (uptake), cost, efficiency of service delivery and client satisfaction – all of which are integral components of effective program planning, implementation and evaluation. Nonetheless, our findings add to the limited body of research into a relatively nascent but rapidly expanding approach to effective HIV care delivery in Sierra Leone and similar resource-limited settings in West Africa.

**Conclusion**

In this pre-implementation analysis, we estimated that about one-third of recent adult HIV clinic attendees at the largest HIV treatment center in Sierra Leone qualified as stable for ART delivery based on the proposed DSD models. While there was high utilization of certain HIV services such as HIV status disclosure and treatment buddy program participation, there was low uptake in partner testing, HIV community support group participation and targeted adherence counselling. About two-thirds of patients with available viral load in the preceding 12 months were virally suppressed. Virologic failure was predicted by low CD4 (<350 cells/mm$^3$), being on ritonavir-boosted atazanavir-based ART, one-monthly versus multi-monthly ART dispensing, history of ART switching, poor treatment adherence and not having received targeted adherence counselling. Our findings suggest that additional resources are needed to bring the program up to readiness for full DSD implementation.

**Acknowledgments**

We wish to thank the HIV Clinic staff at Connaught Hospital in Freetown, Sierra Leone for their dedication to patient care.

**Author contributions**

SL: Study design, data collection, statistical analysis, result interpretation, manuscript writing

DFJ, AOV: Study design, data collection, manuscript writing

EP, OA, GFD, FS, CJH, JMJ, RAS: Result interpretation, manuscript writing

GAY: Study design, funding acquisition, statistical analysis, result interpretation, manuscript writing.

**Disclosure statement**

No potential conflict of interest was reported by the author(s).

**Ethics and consent**

Ethics approval was obtained from the Sierra Leone Ethics Scientific and Research Committee. Clinical data were de-identified, therefore written informed consent was not required for this retrospective study.
**Funding information**

GAY was supported by the Roe Green Travel Medicine and Global Health Award 2019, University Hospitals Cleveland Medical Center (Award Number J0628); Roe Green Travel Medicine Award 2019 [J0628].

**Paper context**

There are limited data to help guide implementation of differentiated HIV service delivery (DSD) in Sierra Leone and other countries in sub-Saharan Africa. This pre-implementation analysis found that about one-third of HIV patients on ART were eligible for DSD. We identified gaps in HIV care (i.e. low partner testing, treatment ‘buddy’, program participation and significant proportion of patients with virologic failure) that need to be addressed in preparation for full implementation of DSD in Sierra Leone.

**ORCID**

Sulaiman Lakoh http://orcid.org/0000-0002-7639-0004  
Eva Poveda http://orcid.org/0000-0003-4835-9875  
Christopher J. Hoffmann http://orcid.org/0000-0002-9422-0519  
Robert A. Salata http://orcid.org/0000-0001-8464-0918  
George A. Yendewa http://orcid.org/0000-0002-8474-1812

**References**

[1] Joint United Nations Programme on HIV/AIDS. UNAIDS data 2020. Geneva: Joint United Nations Programme on HIV/AIDS; 2020 [cited 2021 May 17]. Available from: https://www.unaids.org/sites/default/files/media_asset/2020_aids-data-book_en.pdf

[2] World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. 2nd edition. Geneva: World Health Organization; 2016. [cited 2021 May 17]. Available from: https://apps.who.int/iris/bitstream/handle/10665/208825/9789241549684_eng.pdf?sequence=1

[3] Department of Health and Human Services. Adult and adolescent guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Geneva: Department of Health and Human Services; 2019 [cited 2021 May 17]. Available from: https://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf

[4] European AIDS Clinical Society. Guidelines version 10.0. European AIDS Clinical Society; 2019 [cited 2021 May 17]. Available from: https://www.eacsociety.org/files/2019_guidelines-10.0_final.pdf

[5] International AIDS Society. Differentiated care for HIV: a decision framework for antiretroviral therapy delivery. International AIDS Society, 2018 [cited 2021 May 7]. Available from: http://www.differentiatedcare.org/Portals/0/adam/Content/y56M-GkB3EWs_iTBHk1C1IQ/File/Decision%20Framework.pdf

[6] Joint United Nations Programme on HIV/AIDS. Regional Factsheets-West and Central Africa. Geneva: Joint United Nations Programme on HIV/AIDS; 2018 [cited 2021 May 17]. Available from: https://www.unaids.org/en/regionscountries/westandcentralafrica

[7] International AIDS Society. Prioritizing differentiated ART delivery to fast track reaching HIV targets in West and Central Africa. International AIDS Society; 2017 [cited 2021 May 17]. Available from: http://www.differentiatedcare.org/Portals/0/adam/Content/6Bygnat6lk-Igp5g9juhxw/File/4%20pager%20English%20WEB.pdf

[8] Joint United Nations Programme on HIV/AIDS. UNAIDS data 2019. Geneva: Joint United Nations Programme on HIV/AIDS; 2019 [cited 2021 May 17]. Available from: https://www.unaids.org/sites/default/files/media_asset/2019-UNAIDS-data_en.pdf

[9] Yendewa GA, Poveda E, Yendewa SA, et al. HIV/AIDS in Sierra Leone: characterizing the hidden epidemic. AIDS Rev. 2018;20:104–113.

[10] Yendewa GA, Poveda E, Lakoh S, et al. High prevalence of late-stage disease in newly diagnosed human immunodeficiency virus patients in Sierra Leone. Open Forum Infect Dis. 2018;5:ofo208.

[11] Lakoh S, Jiba DF, Kanu JE, et al. Causes of hospitalization and predictors of HIV-associated mortality at the main referral hospital in Sierra Leone: a prospective study. BMC Public Health. 2019;19:1320.

[12] Yendewa GA, Sahr F, Lakoh S, et al. Prevalence of drug resistance mutations among ART-naive and - experienced HIV-infected patients in Sierra Leone. J Antimicrob Chemother. 2019;74:2024–2029.

[13] International AIDS Society. Guide of differentiated care models in Sierra Leone. International AIDS Society; 2018 [cited 2021 May 17]. Available from: https://www.differentiatedcare.org/Portals/0/adam/Content/AINWnDOUcEKx_l__ltN5LQ/File/Guide%20of%20Differentiated%20care%20Model%20Sierra%20Leone%20-%20Final%20Version%20May%202018.pdf

[14] Wilkinson L, Grimsrud A. The time is now: expedited HIV differentiated service delivery during the COVID-19 pandemic. J Int AIDS Soc. 2020;23:e25503.

[15] The Global Fund to Fight HIV, TB and Malaria. COVID-19 information note: considerations for global fund HIV support. The Global Fund to Fight HIV, TB and Malaria; 2020 [cited 2021 May 18]. Available from: https://www.theglobalfund.org/media/9512/covid19_hiv_infonote_en.pdf

[16] Vandy AO. Prioritized DSD implementation in Sierra Leone due to COVID-19 [cited 2021 May 18]. Available from: https://www.differentiatedcare.org/Portals/0/adam/Content/cqcyYrw2ZXkwlw5-toy0O8w/File/6%20DSD%20in%202020_Vandy_pdf.pdf

[17] Songo ID. Utilizing the network of HIV positives in Sierra Leone (NETHIPS) for DSD during COVID-19 [cited 2021 May 18]. Available from: https://www.differentiatedcare.org/Portals/0/adam/Content/fkjJU9eS8Eyazjsy1IMMow/File/5%20DSD%20in%202020_Songo_pdf.pdf

[18] Joint United Nations Programme on HIV/AIDS. Rights in the time of COVID-19: lessons from HIV for an effective, community-led response. Geneva: Joint United Nations Programme on HIV/AIDS; 2020 [cited 2021 May 18]. Available from: https://www.unaids.org/sites/default/files/media_asset/human-rights-and-covid-19_en.pdf

[19] Hoffman RM, Balakasi K, Bardon AR, et al. Eligibility for differentiated models of HIV treatment service delivery: an estimate from Malawi and Zambia. AIDS. 2020;34:475–479.
[20] World Health Organization. WHO consultation on technical and operational recommendations for scale-up of laboratory services and monitoring HIV antiretroviral therapy in resource-limited settings. Geneva: World Health Organization; 2005 [cited 2021 May 18]. Available from: https://apps.who.int/iris/handle/10665/43344

[21] Roberts T, Cohn J, Bonner K, et al. Scale-up of routine viral load testing in resource-poor settings: current and future implementation challenges. Clin Infect Dis. 2016;62:1043–1048.

[22] Alemnji G, Fonjungo P, Van Der Pol B, et al. The centrality of laboratory services in the HIV treatment and prevention cascade: the need for effective linkages and referrals in resource-limited settings. AIDS Patient Care STDs. 2014;28:268–273.

[23] Kelly JD, Reid MJ, Lahiff M, et al. Community-level HIV stigma as a driver for HIV transmission risk behaviors and sexually transmitted diseases in Sierra Leone: a population-based study. J Acquir Immune Defic Syndr. 2017;75:399–407.

[24] Kelly JD, Weiser SD, Tsai AC. Proximate context of HIV stigma and its association with HIV testing in Sierra Leone: a population-based study. AIDS Behav. 2016;20:65–70.

[25] Lahai M, James PB, Wannang NN, et al. A cross-sectional study on caregivers’ perspective of the quality of life and adherence of paediatric HIV patients to highly active antiretroviral therapy. BMC Pediatr. 2020;20:286.

[26] Nachega JB, Marconi VC, Van Zyl GU, et al. HIV treatment adherence, drug resistance, virologic failure: evolving concepts. Infect Disord Drug Targets. 2011;11:167–174.

[27] Taieb F, Madec Y, Cournil A, et al. Virological success after 12 and 24 months of antiretroviral therapy in sub-Saharan Africa: comparing results of trials, cohorts and cross-sectional studies using a systematic review and meta-analysis. PLoS One. 2017;12:e0174767.

[28] Anude CJ, Eze E, Onyegbutulem HC, et al. Immuno-virologic outcomes and immuno-virologic discordance among adults alive and on anti-retroviral therapy at 12 months in Nigeria. BMC Infect Dis. 2013;13:113.

[29] Obiri-Yeboah D, Pappoe F, Baidoo I, et al. Immunologic and virologic response to ART among HIV infected individuals at a tertiary hospital in Ghana. BMC Infect Dis. 2018;18:230.

[30] Meloni ST, Chang CA, Eisen G, et al. Long-term outcomes on antiretroviral therapy in a large scale-up program in Nigeria. PLoS One. 2016;11:e0164030.

[31] World Health Organization. HIV drug resistance report 2019. Geneva: World Health Organization; 2019 [cited 2021 May 18]. Available from: https://www.who.int/hiv/pub/drugresistance/hivdr-report-2019/en/

[32] World Health Organization. Global action plan on HIV drug resistance (2017-2021). Geneva: World Health Organization; 2017 [cited 2021 May 18]. Available from: https://apps.who.int/iris/bitstream/handle/10665/255883/9789241512848-eng.pdf?sequence=1